1-8 of 8
Michael Grever
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas

Tanios Bekaii-Saab, Joseph Markowitz, Nichole Prescott, Wolfgang Sadee, Nyla Heerema, Lai Wei, Zunyan Dai, Audrey Papp, Angela Campbell, Kristy Culler, Catherine Balint, Bert O'Neil, Ruey-min Lee, Mark Zalupski, Janet Dancey, Helen Chen, Michael Grever, Charis Eng, Miguel Villalona-Calero
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (18): 5895–5901.
https://doi.org/10.1158/1078-0432.CCR-09-0465
Published: 14 September 2009
View article titled, A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas
Open the PDF for A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas in another window
Journal Articles

Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia

Tasneem Motiwala, Sarmila Majumder, Huban Kutay, David Spencer Smith, Donna S. Neuberg, David M. Lucas, John C. Byrd, Michael Grever, Samson T. Jacob
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (11): 3174–3181.
https://doi.org/10.1158/1078-0432.CCR-06-1720
Published: 01 June 2007
View article titled, Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia
Open the PDF for Methylation and Silencing of Protein Tyrosine Phosphatase Receptor Type O in Chronic Lymphocytic Leukemia in another window
Journal Articles

Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Philip Binkley, Kenneth Chan, Jim Xiao, Daria Arbogast, Minden Collamore, Yasser Farra, Donn Young, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (13): 3997–4003.
https://doi.org/10.1158/1078-0432.CCR-05-2689
Published: 03 July 2006
View article titled, Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia

Guowei Dai, Kenneth K. Chan, Shujun Liu, Dale Hoyt, Susan Whitman, Marko Klisovic, TianSheng Shen, Michael A. Caligiuri, John Byrd, Michael Grever, Guido Marcucci
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (8): 2998–3008.
https://doi.org/10.1158/1078-0432.CCR-04-1505
Published: 18 April 2005
View article titled, Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia
Open the PDF for Cellular Uptake and Intracellular Levels of the Bcl-2 Antisense G3139 in Cultured Cells and Treated Patients with Acute Myeloid Leukemia in another window
Journal Articles

Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah, Donn Young, Hedy L. Kindler, Iain Webb, Barbara Kleiber, John Wright, Michael Grever
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6111–6118.
https://doi.org/10.1158/1078-0432.CCR-04-0422
Published: 24 September 2004
View article titled, Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors
Open the PDF for Phase II Study of the Proteasome Inhibitor Bortezomib (PS-341) in Patients with Metastatic Neuroendocrine Tumors in another window
Journal Articles

Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer

Miguel A. Villalona-Calero, M. Guillaume Wientjes, Gregory A. Otterson, Steven Kanter, Donn Young, Anthony J. Murgo, Beth Fischer, Carrie DeHoff, Danny Chen, Teng-Kuang Yeh, SaeHeum Song, Michael Grever, Jessie L-S. Au
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (9): 3303–3311.
Published: 05 September 2003
View article titled, Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for Phase I Study of Low-Dose Suramin as a Chemosensitizer in Patients with Advanced Non-Small Cell Lung Cancer in another window
Journal Articles

Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia

Steven D. Gore, Li-Jun Weng, Suoping Zhai, William D. Figg, Ross C. Donehower, George J. Dover, Michael Grever, Constance A. Griffin, Louise B. Grochow, Eric K. Rowinsky, Yelena Zabalena, Anita L. Hawkins, Kathleen Burks, Carole B. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (8): 2330–2339.
Published: 01 August 2001
View article titled, Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia
Open the PDF for Impact of the Putative Differentiating Agent Sodium Phenylbutyrate on Myelodysplastic Syndromes and Acute Myeloid Leukemia in another window
Journal Articles

Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2′-Deoxycoformycin and Prediction of Early Relapse

Martin S. Tallman, David Hakimian, Kenneth J. Kopecky, Susan Wheaton, Eric Wollins, Kathy Foucar, Peter A. Cassileth, Thomas Habermann, Michael Grever, Jacob M. Rowe, LoAnn C. Peterson
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (7): 1665–1670.
Published: 01 July 1999
View article titled, Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2′-Deoxycoformycin and Prediction of Early Relapse
Open the PDF for Minimal Residual Disease in Patients with Hairy Cell Leukemia in Complete Remission Treated with 2-Chlorodeoxyadenosine or 2′-Deoxycoformycin and Prediction of Early Relapse in another window